Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문병석 | * |
dc.date.accessioned | 2019-10-29T16:30:28Z | - |
dc.date.available | 2019-10-29T16:30:28Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 1078-0432 | * |
dc.identifier.other | OAK-25543 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251652 | - |
dc.description.abstract | Purpose: Cholangiocarcinoma is a malignancy of bile duct with a poor prognosis. Conventional chemotherapy and radiotherapy are generally ineffective, and surgical resection is the only curative treatment for cholangiocarcinoma. L1-cell adhesion molecule (L1CAM) has been known as a novel prognostic marker and therapeutic target for cholangiocarcinoma. This study aimed to evaluate the feasibility of immuno-PET imaging–based radioimmunotherapy using radiolabeled anti-L1CAM antibody in cholangiocarcinoma xenograft model. Experimental Design: We prepared a theranostic convergence bioradiopharmaceutical using chimeric anti-L1CAM antibody (cA10-A3) conjugated with 1,4,7-triazacyclono-nane-1,4,7-triacetic acid (NOTA) chelator and labeled with 64Cu or 177Lu and evaluated the immuno-PET or SPECT/CT imaging and biodistribution with 64Cu-/177Lu-cA10-A3 in various cholangiocarcinoma xenograft models. Therapeutic efficacy and response monitoring were performed by 177Lu-cA10-A3 and 18F-FDG-PET, respectively, and immunohistochemistry was done by TUNEL and Ki-67. Results: Radiolabeled cA10-A3 antibodies specifically recognized L1CAM in vitro, clearly visualized cholangiocarcinoma tumors in immuno-PET and SPECT/CT imaging, and differentiated the L1CAM expression level in cholangiocarcinoma xenograft models. 177Lu-cA10-A3 (12.95 MBq/100 mg) showed statistically significant reduction in tumor volumes (P < 0.05) and decreased glucose metabolism (P < 0.01). IHC analysis revealed 177Lu-cA10-A3 treatment increased TUNEL-positive and decreased Ki-67-positive cells, compared with saline, cA10-A3, or 177Lu-isotype. Conclusions: Anti-L1CAM immuno-PET imaging using 64Cu-cA10-A3 could be translated into the clinic for characterizing the pharmacokinetics and selecting appropriate patients for radioimmunotherapy. Radioimmunotherapy using 177Lu-cA10-A3 may provide survival benefit in L1CAM-expressing cholangiocarcinoma tumor. Theranostic convergence bioradiopharmaceutical strategy would be applied as imaging biomarker-based personalized medicine in L1CAM-expressing patients with cholangiocarcinoma. © 2019 American Association for Cancer Research. | * |
dc.language | English | * |
dc.publisher | American Association for Cancer Research Inc. | * |
dc.title | Development of a theranostic convergence bioradiopharmaceutical for immuno-PET based radioimmunotherapy of L1CAM in cholangiocarcinoma model | * |
dc.type | Article | * |
dc.relation.issue | 20 | * |
dc.relation.volume | 25 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 6148 | * |
dc.relation.lastpage | 6159 | * |
dc.relation.journaltitle | Clinical Cancer Research | * |
dc.identifier.doi | 10.1158/1078-0432.CCR-19-1157 | * |
dc.identifier.wosid | WOS:000494361900017 | * |
dc.identifier.scopusid | 2-s2.0-85073309040 | * |
dc.author.google | Song I.H. | * |
dc.author.google | Jeong M.S. | * |
dc.author.google | Hong H.J. | * |
dc.author.google | Shin J.I. | * |
dc.author.google | Park Y.S. | * |
dc.author.google | Woo S.-K. | * |
dc.author.google | Moon B.S. | * |
dc.author.google | Kim K.I. | * |
dc.author.google | Lee Y.J. | * |
dc.author.google | Kang J.H. | * |
dc.author.google | Lee T.S. | * |
dc.contributor.scopusid | 문병석(22950995100;57206502981) | * |
dc.date.modifydate | 20240318142826 | * |